CD137pos Regulatory T Cells Suppressing Autoimmune Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for T-cell-mediated autoimmune diseases, such as type 1 diabetes, are ineffective in reversing the disease, and there is a need for immune-based treatments that modulate autoreactive T cells to address the disproportionate burden on public health resources and patient morbidity and mortality.
Innovation Solution
Administration of soluble CD137 or CD137-expressing regulatory T cells to mammals in need, utilizing pharmaceutical compositions that include a therapeutically effective amount of these components with a pharmaceutically acceptable carrier, to treat or prevent T-cell-mediated autoimmune diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used for T-cell-mediated autoimmune diseases, then treatment is provided, but the therapies are ineffective in reversing the disease
Solution Approach 1:
The patent introduces regulatory T cells as intermediary agents that mediate the suppression of autoreactive T cells. These regulatory T cells express CD137 and act as mediators to modulate the immune response, bridging the gap between ineffective current therapies and the desired immune modulation effect.
Solution Approach 2:
The patent changes the parameter of T cell regulation by introducing regulatory T cells with specific CD137 expression. This parameter change (adding CD137-expressing regulatory T cells) transforms the immune system's ability to control autoreactive T cells, moving from ineffective therapy to effective disease reversal.
2Ease of manufacture
If autoreactive T cells are not modulated, then current treatment protocols are maintained, but there is a disproportionate burden on public health resources and patient morbidity
Solution Approach 1:
The patent enables the immune system to self-regulate by enhancing the function of regulatory T cells. The therapeutic approach allows the body's own immune system to modulate autoreactive T cells through CD137-expressing regulatory T cells, reducing the need for complex external interventions and thereby reducing public health burden.
3Reliability
If regulatory T cells are not enhanced, then disease progression continues, but enhancing regulatory T cell function requires specific CD137 expression
Solution Approach 1:
The patent applies local quality by specifically enhancing CD137 expression on regulatory T cells rather than uniformly modifying all T cells. This localized enhancement of CD137 on the specific cell type (regulatory T cells) that needs improvement allows for targeted therapy with reduced complexity compared to systemic approaches.
Data Source
AI summary
A method for treating or preventing a T-cell-mediated autoimmune disease is provided herein, the method including administering to a mammal in need thereof a therapeutically effective amount of soluble CD137 or CD137pos regulatory T cells. Also provided are pharmaceutical compositions for treating or preventing T-cell-mediated autoimmune diseases, the pharmaceutical compositions including a therapeutically effective amount of soluble CD137 or CD137pos regulatory T cells and a pharmaceutically-acceptable carrier.